Search Results

The nations most influential science advisory group will tell Congress today that the U.S. pharmaceutical market is not sustainable and needs to change.

Private benefits exchangescommercially marketed platforms on which employees can shop for a wide range of employer-sponsored health and voluntary benefitsare slowly growing and changing in response to market demands.

Reference-based pricing (RBP) is a fast-growing alternative to the PPO systems self-funded employers have utilized for their group benefit plans over the past 30 years.

As soon as news surfaced last week about the potential merger of CVS Health and Aetna, all eyes turned to the looming threat from Amazon.

Since the discounting levels from PPOs are a tightly guarded secret, employers are unaware that they are paying three times what the largest payer in the country has deemed to be fair reimbursement.

Choice in products and plans is at the core of most online benefits marketplaces operating today. Without meaningful choice, a solution would be hard pressed to deliver the results for employee satisfaction that the industry is currently realizing.

Costs for CAR T-cell therapies will be far higher than many have imagined, reaching $1 million or more per patient, according to leading cancer experts. The next CAR T-cell drug could be approved as soon as November.

California Gov. Jerry Brown defied the drug industry Monday by signing a sweeping drug price transparency bill that will force drugmakers to publicly justify big price hikes.